We are live on
!
Find out more
SNNA
Sienna Biopharmaceuticals, Inc.
SNNA
SNNA
Delisted
SNNA was delisted on the 16th of December, 2019.
48 hedge funds and large institutions have $12.3M invested in Sienna Biopharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 17 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
16% less funds holding
Funds holding: 57 → 48 (-9)
35% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 17
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
66% less capital invested
Capital invested by funds: $36.4M → $12.3M (-$24M)
Holders
48
Holders Change
-9
Holders Change %
-15.79%
% of All Funds
1.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
11
Reduced
17
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.42M |
| 2 |
Millennium Management
New York
|
+$451K |
| 3 |
Renaissance Technologies
New York
|
+$440K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$143K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$108K |
Top Sellers
| 1 |
LM
Luminus Management
Houston,
Texas
|
-$2.2M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.86M |
| 3 |
BlackRock
New York
|
-$1.08M |
| 4 |
State Street
Boston,
Massachusetts
|
-$547K |
| 5 |
Morgan Stanley
New York
|
-$210K |
